Doxorubin - PharmaKB

Doxorubin

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

No data

Clinical

Clinical Trials

2553 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Lymphoma	D008223	—	C85.9	138	411	183	15	38	704
Breast neoplasms	D001943	EFO_0003869	C50	92	324	120	13	73	570
Sarcoma	D012509	—	—	65	127	50	5	22	242
Ovarian neoplasms	D010051	EFO_0003893	C56	72	105	65	2	16	229
Large b-cell lymphoma diffuse	D016403	—	C83.3	51	144	52	2	10	228
Carcinoma	D002277	—	C80.0	47	102	41	5	32	205
B-cell lymphoma	D016393	—	—	59	127	45	3	8	205
Non-hodgkin lymphoma	D008228	—	C85.9	46	100	46	5	10	183
Leukemia	D007938	—	C95	42	84	50	8	7	173
Ovarian epithelial carcinoma	D000077216	—	—	55	74	46	2	12	167

Show 38 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Neoplasms	D009369	—	C80	95	59	18	—	7	156
Fallopian tube neoplasms	D005185	—	—	31	32	22	—	1	73
Recurrence	D012008	—	—	24	33	14	—	7	68
Neuroblastoma	D009447	EFO_0000621	—	10	22	16	—	3	51
Osteosarcoma	D012516	—	—	11	20	11	—	8	43
Endometrial neoplasms	D016889	EFO_0004230	—	5	20	18	—	—	41
Neoplasm metastasis	D009362	EFO_0009708	—	15	22	3	—	4	40
Peritoneal neoplasms	D010534	—	—	13	19	7	—	6	40
Adenocarcinoma	D000230	—	—	9	19	9	—	2	33
Ewing sarcoma	D012512	EFO_0000173	—	5	16	7	—	3	29

Show 127 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Stomach neoplasms	D013274	EFO_0003897	C16	5	10	—	—	6	20
Male breast neoplasms	D018567	—	—	5	12	—	—	2	15
Invasive hydatidiform mole	D002820	—	D39.2	2	11	—	—	—	13
Glioblastoma	D005909	EFO_0000515	—	4	8	—	—	—	11
Plasmablastic lymphoma	D000069293	—	C83.3	7	7	—	—	—	11
Large-cell lymphoma immunoblastic	D016400	—	—	7	7	—	—	—	11
Non-small-cell lung carcinoma	D002289	—	—	3	8	—	—	—	10
Adult t-cell leukemia-lymphoma	D015459	—	C91.5	4	6	—	—	—	9
Aids-related lymphoma	D016483	EFO_1001365	—	3	6	—	—	—	9
Urologic neoplasms	D014571	—	C64-C68	4	6	—	—	—	8

Show 137 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Myelodysplastic-myeloproliferative diseases	D054437	—	—	4	—	—	—	—	4
Appendiceal neoplasms	D001063	EFO_0003880	C18.1	2	—	—	—	2	4
Skin neoplasms	D012878	EFO_0004198	C44	1	—	—	—	1	2
Pleural effusion	D010996	—	J90	1	—	—	—	1	2
Pleural neoplasms	D010997	—	—	1	—	—	—	1	2
Castration-resistant prostatic neoplasms	D064129	—	—	1	—	—	—	—	1
Primary myelofibrosis	D055728	—	D47.4	1	—	—	—	—	1
Myelomonocytic leukemia chronic	D015477	—	C93.1	1	—	—	—	—	1
Anemia	D000740	EFO_0004272	D64.9	1	—	—	—	—	1
Leukemia myeloid chronic atypical bcr-abl negative	D054438	—	C92.2	1	—	—	—	—	1

Show 21 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Cardiovascular diseases	D002318	EFO_0000319	I98	—	—	—	—	4	4
Pseudomyxoma peritonei	D011553	EFO_0007456	—	—	—	—	—	2	2
Thrombosis	D013927	—	—	—	—	—	—	2	2
Taste disorders	D013651	—	—	—	—	—	—	1	1
Dysgeusia	D004408	—	R43.2	—	—	—	—	1	1
Ageusia	D000370	EFO_1001758	—	—	—	—	—	1	1
Hepatitis a	D006506	EFO_0007305	B15	—	—	—	—	1	1
Fatigue	D005221	—	R53.83	—	—	—	—	1	1
Ataxia	D001259	—	R27.0	—	—	—	—	1	1
Ataxia telangiectasia	D001260	Orphanet_100	G11.3	—	—	—	—	1	1

Show 36 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	—
INN	—
Description	—
Classification	Unknown
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	—